Related Experiment Video

Updated: Sep 16, 2025

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.0K

Faecal microbiota transplant in Parkinson's disease: pilot study to establish safety & tolerability

Michele De Sciscio1, Robert V Bryant2,3,4, Sarah Haylock-Jacobs3,5

  • 1Neurology Unit, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, Australia. michele.desciscio@sa.gov.au.

NPJ Parkinson'S Disease
|July 9, 2025
PubMed

Insights

Faecal Microbiota Transplantation (FMT) is safe for Parkinson's Disease (PD) patients, offering transient symptom relief. Extended FMT therapy showed potential for reduced motor OFF time but lacked sustained benefits over six months.

Area of Science:

  • Neuroscience
  • Gastroenterology
  • Microbiology

Background:

  • Gut microbiota alterations are increasingly linked to Parkinson's Disease (PD) progression and treatment response.
  • Faecal Microbiota Transplantation (FMT) presents a promising therapeutic avenue for modulating the gut microbiome in PD.

Purpose of the Study:

  • To evaluate the safety and tolerability of FMT in patients with mild to moderate Parkinson's Disease.
  • To assess the impact of FMT on motor and non-motor symptoms of PD over a six-month period.

Main Methods:

  • An open-label pilot study involving 12 patients with mild to moderate PD.
  • FMT administered via enema for a duration of six months.
  • Assessment of safety, tolerability, motor symptoms, non-motor symptoms, and quality of life.

Main Results:

  • FMT was found to be safe and well-tolerated, with only mild, transient gastrointestinal side effects.
  • A trend towards reduced daily 'OFF' time (motor symptom fluctuations) was observed at the two-month mark.
  • Transient improvements in quality of life and non-motor scores were noted at two months but did not persist at six months.

Conclusions:

  • Extended FMT therapy in Parkinson's Disease is safe and tolerable.
  • While FMT demonstrated a potential for reducing motor 'OFF' time and improving non-motor symptoms, these effects were not sustained throughout the six-month treatment duration.

More Related Videos

Murine Fecal Isolation and Microbiota Transplantation07:32

Murine Fecal Isolation and Microbiota Transplantation

Published on: May 26, 2023

4.4K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.3K

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
389
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
716
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
308
What is Monogastric Digestion?01:50

What is Monogastric Digestion?

The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
72.6K